BACKGROUND: Laboratory and clinical data suggest that the anti-angiogenic agent, thalidomide, if combined with cytotoxic agents, may be effective against recurrent glioblastoma multiforme (GBM). OBJECTIVES: To determine 6-month progression-free survival (6PFS) and toxicity of temozolomide plus thalidomide in adults with recurrent GBM. PATIENTS AND METHODS: Eligible patients had recurrent GBM after surgery, radiotherapy, and/or adjuvant chemotherapy. Temozolomide was given at 150-200 mg/m(2)/day on days 1-5 of each 28-day cycle. Thalidomide was given orally at 400 mg at bedtime (days 1-28) and increased to 1,200 mg as tolerated. Patients were evaluated with magnetic resonance imaging scans every 56 days. The study was designed to detect an increase of the historical 6PFS for GBM from 10 to 30%. RESULTS: Forty-four patients were enrolled, 43 were evaluable for efficacy and safety. The study population included 15 women, 29 men; median age was 53 years (range 32-84); median Karnofsky performance status was 80% (range 60-100%). Thirty-six (82%) patients were chemotherapy-naïve. There were 57 reports of toxicity of grade 3 or greater. Non-fatal grade 3-4 granulocytopenia occurred in 15 patients (34%). The objective response rate was 7%. The estimated probability of being progression-free at 6 months with this therapy is 24% [95% confidence interval (C.I.) 12-38%]. The median time to progression is 15 weeks (95% C.I. 10-20 weeks). There was no observed correlation between serum levels of vascular endothelial growth factor, basic fibroblast growth factor, and IL-8 and the 6PFS outcome. CONCLUSION: This drug combination was reasonably safe, but with little indication of improvement compared to temozolomide alone.
BACKGROUND: Laboratory and clinical data suggest that the anti-angiogenic agent, thalidomide, if combined with cytotoxic agents, may be effective against recurrent glioblastoma multiforme (GBM). OBJECTIVES: To determine 6-month progression-free survival (6PFS) and toxicity of temozolomide plus thalidomide in adults with recurrent GBM. PATIENTS AND METHODS: Eligible patients had recurrent GBM after surgery, radiotherapy, and/or adjuvant chemotherapy. Temozolomide was given at 150-200 mg/m(2)/day on days 1-5 of each 28-day cycle. Thalidomide was given orally at 400 mg at bedtime (days 1-28) and increased to 1,200 mg as tolerated. Patients were evaluated with magnetic resonance imaging scans every 56 days. The study was designed to detect an increase of the historical 6PFS for GBM from 10 to 30%. RESULTS: Forty-four patients were enrolled, 43 were evaluable for efficacy and safety. The study population included 15 women, 29 men; median age was 53 years (range 32-84); median Karnofsky performance status was 80% (range 60-100%). Thirty-six (82%) patients were chemotherapy-naïve. There were 57 reports of toxicity of grade 3 or greater. Non-fatal grade 3-4 granulocytopenia occurred in 15 patients (34%). The objective response rate was 7%. The estimated probability of being progression-free at 6 months with this therapy is 24% [95% confidence interval (C.I.) 12-38%]. The median time to progression is 15 weeks (95% C.I. 10-20 weeks). There was no observed correlation between serum levels of vascular endothelial growth factor, basic fibroblast growth factor, and IL-8 and the 6PFS outcome. CONCLUSION: This drug combination was reasonably safe, but with little indication of improvement compared to temozolomide alone.
Authors: M Gelati; E Corsini; S Frigerio; B Pollo; G Broggi; D Croci; A Silvani; A Boiardi; A Salmaggi Journal: J Neurooncol Date: 2003-09 Impact factor: 4.130
Authors: K Neben; T Moehler; G Egerer; A Kraemer; J Hillengass; A Benner; A D Ho; H Goldschmidt Journal: Clin Cancer Res Date: 2001-09 Impact factor: 12.531
Authors: Howard A Fine; Patrick Y Wen; Elizabeth A Maher; Elene Viscosi; Tracy Batchelor; Nehal Lakhani; William D Figg; Benjamin W Purow; Craig B Borkowf Journal: J Clin Oncol Date: 2003-06-15 Impact factor: 44.544
Authors: Victor A Levin; Peter J Tonge; James M Gallo; Marc R Birtwistle; Arvin C Dar; Antonio Iavarone; Patrick J Paddison; Timothy P Heffron; William F Elmquist; Jean E Lachowicz; Ted W Johnson; Forest M White; Joohee Sul; Quentin R Smith; Wang Shen; Jann N Sarkaria; Ramakrishna Samala; Patrick Y Wen; Donald A Berry; Russell C Petter Journal: Neuro Oncol Date: 2015-11 Impact factor: 12.300
Authors: Gao Guo; Ke Gong; Vineshkumar Thidil Puliyappadamba; Nishah Panchani; Edward Pan; Bipasha Mukherjee; Ziba Damanwalla; Sabrina Bharia; Kimmo J Hatanpaa; David E Gerber; Bruce E Mickey; Toral R Patel; Jann N Sarkaria; Dawen Zhao; Sandeep Burma; Amyn A Habib Journal: Neuro Oncol Date: 2019-12-17 Impact factor: 12.300
Authors: Susan M Chang; Kathleen R Lamborn; John G Kuhn; W K Alfred Yung; Mark R Gilbert; Patrick Y Wen; Howard A Fine; Minesh P Mehta; Lisa M DeAngelis; Frank S Lieberman; Timothy F Cloughesy; H Ian Robins; Lauren E Abrey; Michael D Prados Journal: Neuro Oncol Date: 2008-06-17 Impact factor: 12.300
Authors: Camilo E Fadul; Linda S Kingman; Louise P Meyer; Bernard F Cole; Clifford J Eskey; C Harker Rhodes; David W Roberts; Herbert B Newton; J Marc Pipas Journal: J Neurooncol Date: 2008-07-26 Impact factor: 4.130
Authors: Stefania Maraka; Morris D Groves; Aaron G Mammoser; Isaac Melguizo-Gavilanes; Charles A Conrad; Ivo W Tremont-Lukats; Monica E Loghin; Barbara J O'Brien; Vinay K Puduvalli; Erik P Sulman; Kenneth R Hess; Kenneth D Aldape; Mark R Gilbert; John F de Groot; W K Alfred Yung; Marta Penas-Prado Journal: Cancer Date: 2018-10-25 Impact factor: 6.860